CNBC
Disney Slashes Children's Ticket Prices Amid Attendance Slump
- The Walt Disney Company (NYSE: DIS) has unveiled a new series of discounts for children visiting its iconic Disneyland and Disney World parks.
- This strategic move comes amidst a noticeable decline in attendance and hotel occupancy, a trend exacerbated by the inflationary pressures that have made vacations more expensive for families.
- Beginning October 24, Disneyland, located in California, will offer tickets for children aged three to nine at a starting price of $50.
Amazon's Strategic Retreat from Live Audio Resonates Bitter-Sweet Symphony
- Amazon.com Inc (NASDAQ: AMZN) has decided to pull the plug on Amp, its live-audio app introduced in March 2022. Amp was a platform where users could emulate radio DJs, combining music playback with live commentary. This closure comes amidst a series of project terminations by the e-commerce giant.
- However, despite its initial allure, the app's journey has been cut short, a decision that Steve Boom, the head of Amazon's digital music unit, described as complex and well-considered.
Wall Street Journal
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups
- A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments.
- Startups seizing advances in fields such as genomics and artificial intelligence are designing laboratory-developed tests to spot cancer and other illnesses before symptoms arise and to identify optimal therapies.
- But the agency's latest salvo leaves lab companies with less certainty about future regulation, complicating investment and product-development decisions.
Reuters
No Merck's COVID-19 Pill - US Government Ceases Free Distribution
- The U.S. government is set to cease the distribution of free doses of Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral treatment Lagevrio (molnupiravir), by mid-November, shifting its availability to the commercial market.
- The Administration for Strategic Preparedness and Response, a U.S. Department of Health and Human Services division, recently announced this transition, citing the need for the drug to be made available through traditional commercial channels.
Novo Nordisk's Wegovy Success Uplifts Denmark's Economy And Reputation, But With Caution
- Novo Nordisk A/S's (NYSE: NVO) remarkable success with its weight-loss treatment, Wegovy, is not only a cause for celebration but also a source of caution for Denmark.
- In August, the Danish government revised its annual economic growth forecast, crediting Novo's achievements, which have translated into a 1.2% growth compared ...